Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in Cary, North Carolina.

Heron Therapeutics Inc.

Heron Therapeutics ( ($HRTX) ) has issued an update. On October 27, 2025, Heron Therapeutics appointed Thomas Cusack to its Board of Directors, fol...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	HRTX	$1.06	+0.47%	2.11M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	HRTX	$1.06	+0.5%	2.11M
3
4
5
6

HRTX

HRTX

Latest News for HRTX

Get Heron Therapeutics Inc. Data in Excel

Get Heron Therapeutics Inc. Data in Excel